Teriflunomide, aslo known as A77 1726, is the active metabolite of leflunomide. Teriflunomide is an immunomodulatory drug inhibiting pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase. It is uncertain whether this explains its effect on MS lesions. Teriflunomide inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in MS. It has been found that teriflunomide blocks the transcription factor NF-κB. The drug was approved by the FDA on September 13, 2012.
Subramaniam, Palaniraja; Ramasubbu, Chandrasekaran; Athiramu, Selvaraj. Exploiting intramolecular hydrogen bonding for the highly (Z)-selective & metal free synthesis of amide substituted β-aminoenones. Green Chemistry. Volume 19. Issue 11. Pages 2541-2545. Journal; Online Computer File. (2017).
Palle, Venkata Raghavendracharyulu; Bhat, Ramakrishna Parameshwar; Kaliappan, Mariappan; Babu, Jithendra R.; Shanmughasamy, Rajmahendra. A novel process for the preparation of teriflunomide. Assignee Biocon Limited, India. WO 2016203410. (2016).
Li, Guotao; Liu, Bin; Ma, Yaping; Yuan, Jiancheng. A synthetic method of teriflunomide. Assignee Hybio Pharmaceutical Co., Ltd., Peop. Rep. China. CN 104693070. (2015).
Chen, Xinliang; Liu, Bin; Ma, Yaping; Yuan, Jiancheng. Method for preparation of Teriflunomide and its intermediate. Assignee Hybio Pharmaceuticals (Wuhan) Co., Ltd., Peop. Rep. China. CN 103848756. (2014).
Chen, Guohua; Sun, Lichao. A process for preparing teriflunomide. Assignee China Pharmaceutical University, Peop. Rep. China. CN 102786437. (2012).
Deo, Keshav; Patel, Samir; Dhol, Snehal; Sanghani, Sunil; Ray, Vishal. A process for the preparation of teriflunomide. Assignee Alembic Limited, India. WO 2010013159. (2010).
